ERAS (ES cell-expressed Ras) is a member of the Ras family of small GTPases, first identified in embryonic stem (ES) cells. Unlike classical Ras proteins, ERAS lacks critical regulatory domains, rendering it constitutively active. It plays a key role in maintaining ES cell pluripotency and self-renewal by activating the PI3K/Akt signaling pathway, which promotes cell survival, proliferation, and metabolic regulation. ERAS expression is predominantly observed in early embryonic development and is tightly regulated, with minimal activity in most adult tissues. However, dysregulated ERAS has been implicated in various cancers, including gastric, liver, and ovarian cancers, where its overexpression drives uncontrolled cell growth, metastasis, and chemoresistance.
ERAS antibodies are essential tools for studying its expression, localization, and function. They enable detection of ERAS protein in techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research on its role in stem cell biology and oncogenesis. Due to ERAS’s structural uniqueness, specific antibodies are required to distinguish it from other Ras family members. Investigating ERAS may provide insights into regenerative medicine and cancer therapeutics, particularly in targeting hyperactive signaling pathways. Its association with poor prognosis in certain cancers highlights its potential as a diagnostic or therapeutic biomarker.